» Articles » PMID: 31890590

The Nature and Impact of Neurobehavioral Symptoms in Neuronopathic Hunter Syndrome

Overview
Specialty Endocrinology
Date 2020 Jan 1
PMID 31890590
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

In neuronopathic Hunter syndrome, neurobehavioral symptoms are known to be serious but have been incompletely described. While families face significant stress stemming from this complex and far-reaching array of symptoms, neither caregiver burden nor the neurobehavioral symptoms have been measured comprehensively. We delineated these neurobehavioral characteristics and their impact on the caregiver using multiple approaches. Methods: As part of the initial phase of developing a Hunter-specific behavioral assessment tool, we used multiple methods to obtain data on patient behaviors and caregiver burden, with the intention of drafting item sets for the tool. We utilized 1) caregiver descriptions from focus groups and individual interviews, 2) observations from video-recorded play of affected children, 3) descriptions from historic chart review, 4) consultation with patient advocacy groups and international experts, 5) reports from a caregiver advisory board, and 6) literature review. Results: Neurobehavioral symptoms were diverse and categorized as focus/attention, impulsivity/heightened activity, sensation seeking, emotional/behavioral function, social interaction, and sleep. A significant reported challenge was susceptibility to misinterpretation of some behaviors as defiant or aggressive, particularly if physical. Caregiver burden involved social isolation, exhaustion, stress, and financial and vocational strain. These new descriptions will aid in developing quantitative measures of change in neurobehavioral symptoms and family burden. These descriptions will be the foundation of a neurobehavioral rating scale, which is very much needed to aid in patient management and assess interventions for individuals with neuronopathic Hunter syndrome.

Citing Articles

Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond.

Zanetti A, Tomanin R BioDrugs. 2024; 38(5):639-655.

PMID: 39177874 PMC: 11358193. DOI: 10.1007/s40259-024-00675-0.


Case Report: Holistic dental care for a child with Hunter syndrome: Addressing dental ramifications, overcoming challenges, and enhancing quality of life.

Saha S, Priya K, Rai K, R M, Shetty K, M Hegde A F1000Res. 2024; 13:268.

PMID: 38812528 PMC: 11134137. DOI: 10.12688/f1000research.146468.1.


Mucopolysaccharidosis type II zebrafish model exhibits early impaired proteasomal-mediated degradation of the axon guidance receptor Dcc.

Manzoli R, Badenetti L, Bruzzone M, Macario M, Rubin M, Maschio M Cell Death Dis. 2024; 15(4):269.

PMID: 38627369 PMC: 11021486. DOI: 10.1038/s41419-024-06661-2.


Caregiver experiences and observations of intrathecal idursulfase-IT treatment in a phase 2/3 trial in pediatric patients with neuronopathic mucopolysaccharidosis II.

Yee K, Lewis S, Evans E, Romano C, Alexanderian D Orphanet J Rare Dis. 2024; 19(1):110.

PMID: 38462612 PMC: 10926613. DOI: 10.1186/s13023-024-03034-y.


Analysis of caregiver perspectives on patients with mucopolysaccharidosis II treated with pabinafusp alfa: results of qualitative interviews in Japan.

Nakamura K, Sakai N, Hossain M, Eisengart J, Yamamoto T, Tanizawa K Orphanet J Rare Dis. 2024; 19(1):104.

PMID: 38454486 PMC: 10921713. DOI: 10.1186/s13023-024-03112-1.


References
1.
Muenzer J, Jones S, Tylki-Szymanska A, Harmatz P, Mendelsohn N, Guffon N . Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry. Orphanet J Rare Dis. 2017; 12(1):82. PMC: 5414331. DOI: 10.1186/s13023-017-0635-z. View

2.
Shapiro E, Lourenco C, Onenli Mungan N, Muschol N, ONeill C, Vijayaraghavan S . Analysis of the caregiver burden associated with Sanfilippo syndrome type B: panel recommendations based on qualitative and quantitative data. Orphanet J Rare Dis. 2019; 14(1):168. PMC: 6615275. DOI: 10.1186/s13023-019-1150-1. View

3.
Barone R, Pellico A, Pittala A, Gasperini S . Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses. Ital J Pediatr. 2018; 44(Suppl 2):121. PMC: 6238256. DOI: 10.1186/s13052-018-0561-2. View

4.
Muenzer J, Beck M, Eng C, Escolar M, Giugliani R, Guffon N . Multidisciplinary management of Hunter syndrome. Pediatrics. 2009; 124(6):e1228-39. DOI: 10.1542/peds.2008-0999. View

5.
Holt J, Poe M, Escolar M . Early clinical markers of central nervous system involvement in mucopolysaccharidosis type II. J Pediatr. 2011; 159(2):320-6.e2. DOI: 10.1016/j.jpeds.2011.03.019. View